Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Licensing Agreement with Cipher Pharmaceuticals
Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Distribution Agreement with Cipher Pharmaceuticals
New York – April 1, 2015 – Securities and Corporate law firm Sichenzia Ross Friedman Ference LLP has announced today that the Firm represented Can-Fite Biopharmaceuticals Ltd., (NYSE MKT: CANF) an Israeli biopharmaceutical company developing therapeutic products, in a multi million dollar Distribution Agreement where Cipher Pharmaceuticals, Inc. will distribute Can-Fite’s leading drug candidate, CF101 in the Canadian market for certain indications upon receipt of regulatory approval.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Greg Sichenzia and Gary Emmanuel.
- Sichenzia Ross Ference LLP Represents Aegis Capital in $48.3 Million Underwritten Public Offering of Farmmi, Inc. - May 3, 2021
- Sichenzia Ross Ference LLP Wins Appeal Before the Second Circuit in a Lawsuit Brought By Investors in Connection with a Private Placement - April 30, 2021
- Sichenzia Ross Ference LLP Represents American Battery Metals Corporation in a $15.0 Million Registered Direct Offering - April 29, 2021